Kett, Daniel H.

Anidulafungin versus Fluconazole for Invasive Candidiasis

Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 894

Multicenter Clinical Evaluation of the (1->3) -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans

Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 669

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects

Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 495

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*

Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 389

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting

Ostrosky-Zeichner, L., Sable, C., Sobel, J., Alexander, B. D., Donowitz, G., Kan, V., Kauffman, C. A., Kett, D., Larsen, R. A., Morrison, V., et al. (2007) · European Journal of Clinical Microbiology & Infectious Diseases

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 369

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: An observational, multicentre cohort study.

Kett, D. H., Cano, E., Quartin, A. A., Mangino, J. E., Zervos, M. J., Peyrani, P., Cely, C. M., Ford, K. D., Scerpella, E. G., & Ramirez, J. A. (2011) · The Lancet Infectious Diseases

Nosocomial Infections in ICUAntibiotic Use and Resistance

Cited by 235

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.

Vazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R. (2014) · BMC Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 101

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 88